ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.

Zacks Investment Research • Jun 18, 2026

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.

Zacks Investment Research • May 25, 2026

ImmuCell Q1 Earnings Call Highlights

ImmuCell NASDAQ: ICCC reported a record first quarter of 2026, with management saying the company's narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.

MarketBeat • May 15, 2026

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 15, 2026

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended March 31, 2026.

GlobeNewsWire • May 14, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended March 31, 2026 after the market closes on Thursday, May 14, 2026. The Company is planning to host a conference call on Friday, May 15, 2026, at 9:00 AM ET to review the unaudited financial results.

GlobeNewsWire • May 7, 2026

The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell

Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.

Zacks Investment Research • Apr 22, 2026

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette and Dr. Anthony DiMarco have been appointed to its Board of Directors, effective April 15, 2026. The Company also announced it is moving to a 7-person Board of Directors with six Independent Directors and the CEO, and that it will create a Strategy and Technology Committee of the Board of Directors.

GlobeNewsWire • Apr 13, 2026

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026.

GlobeNewsWire • Apr 8, 2026

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018.

GlobeNewsWire • Mar 18, 2026